Cell-based therapeutics developer ReNeuron Group has announced it has established an office in Boston.

The office will initially house ReNeuron’s US-based clinical, medical and scientific communications staff and reflects the company’s focus on clinical development activities in the US across its therapeutic programmes.

During 2018, ReNeuron plan to have three placebo-controlled Phase IIb clinical trials running with its CTX and hRPC cell therapy candidates, in stroke disability and retinal diseases. All of these studies will be conducted in clinical trial centres across the US.

The establishment of a US office will enable ReNeuron to more closely manage its relationships with the clinical research organisations and others involved in the conduct of these clinical trials as well as facilitating stronger ties with US-based key opinion leaders in ReNeuron’s areas of therapeutic focus.

Olav Hellebø, Chief Executive Officer of ReNeuron, said “We are delighted to have established operations in Boston, one of the US’s most vibrant academic and commercial biotechnology hubs. The US is a major future market for our cell-based therapies and a presence on the ground represents a key element of ReNeuron’s clinical and commercial development strategy as our therapeutic candidates move closer to market.”